In December 2019, a novel infectious disease, later named COVID-19, was reported in Wuhan, China.
1 COVID-19 is characterized by a clinical presentation ranging from asymptomatic to severe, the latter of which includes cytokine storm.
2,3 Older patients or those affected by comorbidities such as cardiovascular diseases, diabetes, or obesity are particularly susceptible to development of severe forms of COVID-19 and are at very high risk for death.
4,5 After the initial outbreaks in the Chinese province of Hubei, the COVID-19 pandemic has rapidly spread across the world.
6 Despite concerns about the burden of the COVID-19 pandemic in Africa, African countries, with the exception of South Africa, have reported a relatively low number of cases and a low rate of daily increases in infection.
7 In Gabon, the first case of COVID-19 was imported from France and reported on March 12, 2020. On March 22, 2020, the Gabonese government established a curfew and partial confinement, including a travel ban on the entire national territory. Three months later, the epidemiologic situation progressed with significant community transmission. By June 15, 2020, 3463 cases of COVID-19 were confirmed, including 23 deaths (a case-fatality rate of 0.66%); by September 2020, 8984 cases of COVID-19 were confirmed, including 55 deaths (a case-fatality rate of 0.61%). This study is focused on the early part of the COVID-19 pandemic in Gabon, when there were initially 2 epidemic foci: Libreville, the national capital on the Atlantic coast, and Franceville in the inner part of the country (eFigure in the Supplement). To date, only 1 retrospective study has been conducted in Gabon
8; it highlighted cross-reactivity against SARS-CoV-2 nucleocapsid (N) antigen among 23% of samples collected in 2014. To our knowledge, the clinical and epidemiologic characteristics of patients with COVID-19 in Libreville, Gabon, have not yet been described.